Cellebrite (CLBT) officer details share, RSU, PSU and option holdings

Rhea-AI Filing Summary

Cellebrite DI Ltd. executive Armon Ronnen filed an initial statement of beneficial ownership, detailing his equity position in the company. As of March 18, 2026, he directly holds 277,844 Ordinary Shares, including shares represented by restricted share units and performance share units that vest over time and based on performance conditions.

Ronnen also holds several stock option grants over Ordinary Shares, including 60,606 underlying shares at an exercise price of $6.60 expiring on February 15, 2032, 80,808 underlying shares at $4.95 expiring on February 13, 2033, and two grants each covering 43,440 underlying shares at $11.51 expiring on March 19, 2034. Footnotes explain which portions are already fully vested and which will vest between May 14, 2026 and March 20, 2029, as well as performance-based awards tied to total shareholder return targets through March 20, 2028.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Armon Ronnen

Role See Remarks

Type	Security	Shares	Price	Value
holding	Stock options	--	--	--
holding	Stock options	--	--	--
holding	Stock options	--	--	--
holding	Stock options	--	--	--
holding	Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	--	--	--

Holdings After Transaction: Stock options — 60,606 shares (Direct); Ordinary shares, par value NIS 0.00001 ("Ordinary Shares") — 277,844 shares (Direct)

Footnotes (1)

1. Includes 29,320 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 7,330 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement. Includes 24,030 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,670 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028. Includes 27,768 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,136 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029. Includes 5,341 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement. Includes 5,341 Ordinary Shares that are represented by PSUs that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. These stock options are fully vested and exercisable. Of these stock options, 60,608 are fully vested and exercisable and 5,050 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Of these stock options, 19,005 are fully vested and exercisable and 2,715 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028. Of these stock options, 15,204 are fully vested and exercisable and 2,172 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Armon Ronnen

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	277,844(1)(2)(3)(4)(5)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options	(6)	02/15/2032	Ordinary Shares	60,606	$6.6	D
Stock options	(7)	02/13/2033	Ordinary Shares	80,808	$4.95	D
Stock options	(8)	03/19/2034	Ordinary Shares	43,440	$11.51	D
Stock options	(9)	03/19/2034	Ordinary Shares	43,440	$11.51	D

Explanation of Responses:

1. Includes 29,320 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 7,330 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

2. Includes 24,030 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,670 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

3. Includes 27,768 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,136 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.

4. Includes 5,341 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.

5. Includes 5,341 Ordinary Shares that are represented by PSUs that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028.

6. These stock options are fully vested and exercisable.

7. Of these stock options, 60,608 are fully vested and exercisable and 5,050 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027.

8. Of these stock options, 19,005 are fully vested and exercisable and 2,715 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

9. Of these stock options, 15,204 are fully vested and exercisable and 2,172 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.

Remarks:

Chief Products & Technologies Officer

	/s/ Ronnen Armon	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Armon Ronnen Form 3 for Cellebrite (CLBT) show?

The Form 3 shows Armon Ronnen’s initial equity holdings in Cellebrite DI Ltd., including 277,844 Ordinary Shares and multiple stock option grants over additional shares. It establishes his starting ownership position as a company officer.

How many Cellebrite (CLBT) Ordinary Shares does Armon Ronnen report owning?

Armon Ronnen reports direct ownership of 277,844 Ordinary Shares of Cellebrite DI Ltd. Footnotes clarify that this figure includes shares represented by RSUs and PSUs that vest over time and may depend on performance conditions through 2028 and 2029.

What stock options are reported for Armon Ronnen in the Cellebrite (CLBT) Form 3?

Ronnen reports stock options over 60,606 shares at $6.60 expiring in 2032, 80,808 shares at $4.95 expiring in 2033, and two grants of 43,440 shares each at $11.51 expiring in 2034, all on Ordinary Shares.

How do RSUs factor into Armon Ronnen’s Cellebrite (CLBT) holdings?

Ronnen’s holdings include Ordinary Shares represented by restricted share units (RSUs) granted in 2023 and 2024. These RSUs vest in quarterly installments beginning in 2026 and continuing through 2028, each RSU converting into one Ordinary Share upon settlement.

What performance share units (PSUs) are disclosed for Armon Ronnen at Cellebrite (CLBT)?

The filing notes PSUs representing 5,341 Ordinary Shares in two separate references. These PSUs vest only if Cellebrite meets specified total shareholder return thresholds for 60 consecutive trading days through March 20, 2028, then settle into Ordinary Shares.

Are Armon Ronnen’s Cellebrite (CLBT) stock options fully vested?

Some options are fully vested, while others vest over time. Footnotes state certain blocks are already fully vested and exercisable, with remaining portions vesting in equal quarterly installments from May 14, 2026 or March 20, 2026 through dates in 2027, 2028, and 2029.